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Available online 17 February 2006Most human melanomas express Fas receptor on the cell surface, and treatment with
exogenous Fas Ligand (FasL) efficiently induces apoptosis of these cells. In contrast,
endogenous surface expression of FasL is suppressed in Fas-positive melanomas. We report
here the use of a combination of sodium arsenite, an inhibitor of NF-κB activation, and
NS398, a cyclooxygenase-2 (COX-2) inhibitor, for restoration of the surface FasL expression.
We observed a large increase of Fas-mediated apoptosis in Fas-positive melanomas. This
was due to induction of FasL surface expression and increased susceptibility to Fas death
signaling after arsenite and NS398 treatment. Furthermore, silencing COX-2 expression by
specific RNAi also effectively increased surface FasL expression following arsenite
treatment. Upregulation of the surface FasL levels was based on an increase in the
efficiency of translocation to the cell surface and stabilization of FasL protein on the cell
surface, rather than on acceleration of the FasL gene transcription. Data obtained
demonstrate that the combination of arsenite with inhibitors of COX-2 may affect the
target cancer cells via induction of FasL-mediated death signaling.
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RNAi, RNA interfering
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Death receptors Fas (CD95/APO-1) and TRAIL Receptors-1
and-2 (DR4 and DR5) are present in a variety of tissues and
play an important role in the regulation of general tissue
homeostasis [1,2]. On the other hand, cancer development
is often accompanied by the suppression of the surface Fas
receptor expression and/or inactivation of the Fas-mediated
signaling, potentially resulting in an inhibition of immuno-
logical anticancer surveillance in vivo [3]. In some highly
metastatic cancer cells, including Fas-negative melanomas,
Fas Ligand (FasL) surface expression is restored, providing
an additional mechanism to suppress anticancer immune
effector cells (so called “tumor counterattack”) [4,5]. Alter-
natively, secretion of processed “soluble” FasL [6] or FasL-
bearing microvesicles [7] by cancer cells may create a
specific shield, which allows them to dampen the effects
of cytotoxic lymphocytes or natural killer cells. A role of
endogenous FasL expression in the “tumor counterattack”
hypothesis is still under active investigation [3,8,9]; howev-
er, experimental data certainly demonstrated FasL expres-
sion in some cancer cell lines, including melanomas
[6,7,10,11]. Taken together, these observations illustrate
important aspects of the general problem of the resistance
of cancer cells to the induction of programmed cell death.
Many recent investigations in the area of cancer therapy
have been focused on the problem of overcoming resistanceto programmed cell death and to restore the ability of
cancer cells to undergo apoptosis [12,13]. An effective
approach was the FasL gene transfer for induction of
apoptosis in Fas-positive cancer cells and tumor regression
in vivo [14–16].
Human melanoma, the most aggressive form of the skin
cancer, is highly resistant to treatment with γ-irradiation or
anticancer drugs and has altered and inhibited apoptotic
signaling pathways [13,17]. Furthermore, human melano-
mas actively suppress the immune system [18–20]. Despite
the dramatic increase in the incidence of this tumor in the
past decades, the molecular mechanisms of its progression
and resistance to apoptosis remain largely unknown.
Melanoma cells express many different growth factors,
cytokines and their receptors (including TNFα/TNFR1) for
regulation of their growth and progression [19,21]. Tumor
necrosis factor alpha (TNFα) mediates a variety of biological
functions such as cell proliferation, differentiation and cell
death. TNFα–TNFR interactions generate two different
signaling cascades: the death signaling pathway (via
TRADD/FADD/Caspase-8) and the survival pathway, in
which the signal adapter TNFR-associated factor-2 (TRAF2)
plays a primary regulatory role [22, 23]. Upon stimulation of
TNFR1 with TNFα, TRAF2 has been implicated in the
activation of transcription factors NF-κB and c-Jun via
inhibitor nuclear factor kappa B kinase (IKK) and Jun N-
terminal kinase (JNK), respectively. The critical component
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complex IKK that phosphorylates the NF-κB inhibitor, IκBα
at Ser 32 and 36 [24]. Phospho-IκBα is then targeted for
proteasome-dependent degradation, thus liberating NF-κB
p65–p50, which enters the nucleus and mediates NF-κB-
dependent transcription of more than 150 genes [25,26].
Thus, NF-κB-dependent gene expression provides a delicate
balance between cell survival functions and cell death by
controlling genes encoding proteins with anti-apoptotic
(FLIP, c-IAP, XIAP, Bcl-xL, TRAF1, TRAF2, COX-2) and pro-
apoptotic functions (Fas, FasL, TRAIL) [24,27,28]. Cyclooxygen-
ase (COX) enzymes catalyze the synthesis of prostaglandins
from arachidonic acid [29,30]. The cyclooxygenase-2 (COX-2)
genepromoter contains the κB- andCRE sites, and its activity is
critically dependent on NF-κB, AP-1 and CREB/ATF2 transcrip-
tion factors [31]. In normal cells, COX-2 gene is highly inducible
by signals that activate the IKKβ–NF-κB pathway. In contrast,
many types of cancer cells possess high basal levels of
COX-2, due to permanent activation of NF-κB in these cells
followed by expression of the COX-2 gene [29,32]. The
downstream product of COX-2 enzymatic activity is pros-
taglandin E2 (PGE2), which serves as an important stimulus
for induction of several cell signaling pathways, including
the NF-κB pathway that subsequently regulates cell prolif-
eration and motility. Indeed, inhibition of COX-2 enzymatic
activity by specific pharmacological inhibitors is an effec-
tive tool for controlling both inflammation and, in some
cases, cancer development [29,32].
In recent publications, we and others have proposed a
number of different approaches for enhancing melanoma
response to anticancer treatment. These include suppression
of NF-κB activity by sodium arsenite treatment or by over-
expression of the stable NF-κB inhibitor IκBΔN [33,34],
combined treatment with sodium arsenite and EGFR inhibi-
tors [35], selective inhibition of transcription factor ATF2
activation by the cognate peptide competitor [36,37], over-
expression of transfected FasL in Fas-positive melanomas
[16] and upregulation of the surface Fas receptor levels in
metastatic melanomas [38]. Suppression of the NF-κB-
dependent expression of survival proteins and inhibition of
the PI3K-AKT pathway have been linked to a dramatic
increase in the sensitivity of cancer cells to endogenous
TNFα and TRAIL [24,39,40]. The aim of the present study was
to test whether restoration of endogenous surface expression
of FasL in Fas-positive melanomas could facilitate apoptosis
of these cancer cells. We found that the combined treatment
of melanoma cells with sodium arsenite and NS398, an
inhibitor of COX-2, would be an effective tool for induction of
cancer cell apoptosis. Surprisingly, such combined treatment
did not activate the FasL promoter activity and FasL
transcription in melanomas but dramatically affected FasL
translocation and expression on the cell surface.Methods
Materials
Sodium arsenite and cycloheximide were obtained from
Sigma (St. Louis, MO). NS398, a selective inhibitor of COX-2,was purchased from Cayman Chemical Company (Ann
Arbor, Michigan). Tumor necrosis factor alpha (TNFα) was
purchased from Roche (Indianapolis, IN); recombinant
human IL-1β was obtained from R&D Systems (Minneapolis,
MN). Human soluble Fas Ligand (recombinant) was pur-
chased from Alexis (San Diego, CA). BD Cytofix/Cytoperm
kit was obtained from BD Pharmingen (San Diego, CA).
Caspase inhibitors zVAD-fmk, Ac-IETD-CHO (an inhibitor of
caspase-8 and caspase-6) and Ac-LEHD-CHO (an inhibitor of
caspase-9) were purchased from Calbiochem (La Jolla, CA).
Matrix metalloproteinase (MMP) inhibitors GM1439, MMP
inhibitor II and MMP inhibitor III were obtained from
Calbiochem (La Jolla, CA). Pre-cast SDS-polyacrylamide gels
were purchased from BioRad (Hercules, CA).
Cell lines
Human melanoma cell lines WM35, SBcl2, LU1205 (also
known as 1205lu), WM9, WM793 [18,21,41,42] and OM431
were maintained in DMEM medium supplemented with
10% fetal bovine serum, L-glutamine and antibiotics. FEMX,
HHMSX and LOX, human melanoma lines [43] were
maintained in RPMI1640 medium supplemented with 10%
FCS and antibiotics. Normal human melanocytes were
obtained from the Department of Dermatology, Yale
University (New Haven, CT) and maintained in TICVA
medium for normal human melanocytes, as recommended
by the manufacturer.
Transfection and luciferase assay
The NF-κB luciferase reporter containing two κB binding
sites, Jun2-Luc reporter and vector tk-Luc [44], were used
for determination of NF-κB and AP-1 transactivation; the
FasL promoter activity was determined using reporter −453
FasLpr-Luc [45] and −1.2 kb FasLpr-Luc [46]; the Fas
promoter activity was determined using −460 FASpr-Luc
reporter [38]. Transient transfection of different reporter
constructs (1 μg) together with pCMV-βGal (0.25 μg) into
5 × 105 melanoma cells was performed using Lipofectamine
(Life Technologies/Invitrogen, Carlsbad, CA). Proteins were
prepared for βGal and luciferase analysis 16 h after
transfection. Luciferase activity was determined using the
luciferase assay system (Promega, Madison, WI) and was
normalized based on β-galactosidase levels. In some
experiments, melanoma cells were transfected with GFP-
FasL expression construct [47,48].
RNAi targeting of COX-2 mRNA
The empty vector pSR-GFP/Neo was obtained from Oligoen-
gine (Seattle, WA). RNAs of 19 nucleotides (ACGUUGU-
GAAUAACAUUCC), designed to target human COX-2 mRNA
within nucleotides 354–372, were expressed using pSR-GFP/
Neo (Cox-2-RNAi) plasmid construct, which also produced a
marker GFP protein. Human melanoma cells with perma-
nent expression of COX-2 have been used for COX-2
targeting. Melanoma cells were transfected with indicated
expression vectors using Lipofectamine (Life Technologies/
Invitrogen, Carlsbad, CA).
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Cells were exposed to sodium arsenite (1–20 μM) in the
medium for 6–48 h. NS398 (50 μM), an inhibitor of COX-2
activity, was used with or without 5–10 μM sodium
arsenite. Antibodies against TNFα, FasL (BD Pharmingen,
San Diego, CA) and TRAIL (Alexis, San Diego, CA) were
added (1–5 μg/ml) 1 h before sodium arsenite treatment.
Apoptosis was assessed by quantifying the percentage of
hypodiploid nuclei undergoing DNA fragmentation [49] or
by quantifying the percentage of Annexin-V-FITC-positive
cells (BD Pharmingen, San Diego, CA) or Annexin-V-PE (red
fluorescence) positive cells in case of GFP-transfected
(green) cells. Flow cytometric analysis was performed on a
FACS Calibur flow cytometer (Becton Dickinson) using the
CellQuest program.
FACS analysis of Fas, FasL and COX-2 levels
Surface and total (after cell permeabilization with BD
Cytofix/Cytoperm) levels of Fas, FasL or COX-2 were deter-
mined by staining with the correspondent PE-conjugated
anti-human mAb (for Fas) or with primary mAb (for FasL or
COX-2) and PE-conjugated goat anti-mouse secondary Ab
and subsequent flow cytometry. Flow cytometric analysis
was performed with 40,000 cells for single color staining and
with 80,000 cells for double color staining using a FACS
Calibur flow cytometer (Becton Dickinson, Mountain View,
CA) with CellQuest program. All experiments were indepen-
dently repeated 3–5 times.
Western blot analysis and immunoprecipitation
Total cell lysates (50–100 μg protein) were resolved on 10%
SDS-PAGE and processed according to standard protocols.
The antibodies used for Western blotting were polyclonal
anti-phospho-AKT (Ser 473), control anti-AKT (Cell Signal-
ing, Beverly, MA), monoclonal anti-β-actin (Sigma), mono-
clonal anti-COX-2 from Cayman Chemical Company (Ann
Arbor, Michigan), polyclonal anti-heme-oxygenase-1 (Stress-
gen, Victoria, BC, Canada), polyclonal anti-Bcl-xL (Santa
Cruz, CA) and monoclonal anti-Fas and anti-FasL (BD
Pharmingen, San Diego, CA). Optimal dilutions of primary
Abs were 1:1000 to 1:10,000. The secondary Abs (anti-rabbit
or anti-mouse) were conjugated to horseradish peroxidase
(dilution 1:5000 to 1:10,000). Signals were detected using the
ECL system (Amersham, Piscataway, NJ). Total levels of
FasL were also determined using immunoprecipitation of
total or membrane cell extracts with anti-FasL mAb (NOK-1)
and G-protein Sepharose beads (Sigma) followed by West-
ern blotting with anti-FasL mAb (clone G247-4) (BD Phar-
mingen, San Diego, CA).
Electrophoretic mobility shift assay (EMSA)
Electrophoretic mobility shift assay (EMSA) was per-
formed for detection of NF-κB DNA-binding activity, as
previously described [50] using the labeled double-strand
oligonucleotide AGCTTGGGGACTTTCCAGCCG (binding sites
are underlined).Results
Fas receptor and Fas Ligand expression in human melanomas
Analysis of the surface Fas receptor levels in melanocytes and
in nine lines of human melanoma cell lines (Fig. 1A) has
confirmed and extended previous observations that most
melanomas (both primary and metastatic) have moderate to
high levels of Fas on cell surface. However, some metastatic
melanomas (such as FEMX, HHMSX and OM431) exhibited
significantly decreased levels of surface Fas expression due
either to an inactivation of Fas gene transcription or translo-
cation of Fas protein from the cytoplasm to the plasma
membrane [16,38,51,52]. In contrast, LU1205, a metastatic
melanoma line [18,21], possesses high surface levels of Fas
(Figs. 1A, B) while simultaneously exhibiting some canonical
anti-apoptotic activities, such as (phospho-Ser 473)AKT,NF-κB
p65–p50 and NF-κB-dependent anti-apoptotic Bcl-xL expres-
sion (Fig. 1C). WM9 metastatic melanoma cells also have high
NF-κB p65–p50 but substantially lower phospho-AKT levels
compared to LU1205 cells, while WM793 primary melanoma
cells possess both very low basal NF-κB p65–p50 DNA-binding
activity and almost complete loss of phospho-AKT (Fig. 1C).
Furthermore, all three melanoma lines demonstrated high
total levels of Fas and low tomodest intracellular levels of FasL
(Fig. 1C). The treatment of melanoma cells with high doses (50
ng/ml) of soluble recombinant Fas Ligand (FasL) in the
presence of cycloheximide (2 μg/ml) induced FasL-mediated
apoptosis in most Fas-positive melanomas. However, it was
evident that metastatic melanoma LU1205 was notably less
sensitive to the FasL treatment, compared to the primary
WM793melanoma (in spite of similar levels of surface Fas, see
Fig. 1B), likelydue tomorepronouncedanti-apoptotic activities
mediated by increased phospho-AKT, NF-κB p65–p50 and Bcl-
xL levels.WM9 cells demonstrated intermediate levels of FasL-
induced apoptosis (Figs. 1C and D). Finally, FEMX metastatic
melanoma cells with low surface Fas levels were only slightly
sensitive to FasL-mediated apoptosis (data not shown).
Hence, differences in the surface Fas levels and/or
susceptibility to Fas-mediated death signaling may strongly
affect the apoptotic response of melanoma cells. As a result,
FasL–Fas-mediated apoptosis of cancer cells could be, in
principle, a powerful strategy for anticancer therapy [14,15].
Unfortunately, in vivo, a number of problems are encountered
such as severe systematic liver toxicity of FasL, FasL-based
fusion proteins or agonistic anti-Fas monoclonal antibodies
that greatly reduce the efficacy of these reagents in antican-
cer treatment, despite numerous attempts to overcome this
problem over the past few years [1,53]. As an alternative to
systemic treatment with FasL, an approach based on locally
restricted upregulation of the membrane form of FasL on the
surface of cancer cells could be a promising tool for induction
of apoptosis among cancer cells [14].
In our previous studies, we have used sodium arsenite as
an inducer of cell death in a variety of cancer cells, including
melanomas. Sodium arsenite treatment may stimulate
apoptosis, necrosis or a combination of cell death types
depending of the cell line and sodium arsenite concentration
[34,54,55]. Unfortunately, the vast majority of melanoma cell
Fig. 1 – FasL-mediated apoptosis in human melanomas. (A, B) Surface and total (after cell permeabilization) Fas levels were
determined by staining with PE-conjugated anti-human Fas mAb and flow cytometry of melanocytes (Melano) and indicated
human melanoma cell lines. (C) Western blot analysis of P-AKT, AKT, Bcl-xL, FasL and Fas levels in indicated melanoma cell
lines. EMSA was performed for determination of NF-κB DNA-binding activity. Free labeled oligonucleotide probe (FP) is
indicated. (D) Cell cycle–apoptosis analysis of human melanoma lines WM9, WM793 and LU1205 24 h after treatment with
soluble recombinant FasL (50 ng/ml) and CHX (2 μg/ml). Percentages of apoptotic cells are indicated.
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sodium arsenite, which may induce apoptosis only in some
sensitive cell lines, such as WM793 and FEMX, via TNFR-
mediated pathway [34]. In WM793 cells, there was a direct
correlation between the dose of arsenite (2–20 μM) and levels
of apoptosis [34]. At the higher doses of arsenite (N20 μM),
pronounced secondary necrosis was also observed. Sodium
arsenite is a powerful inhibitor of IKKβ and NF-κB activation
[34,56,57]. We initially demonstrated the dose responseFig. 2 – Sodium arsenite modulates NF-κB activity, FAS and Fas
(A) Dose-dependent effect of sodium arsenite treatment on NF-κ
DNA-binding activity. Free labeled oligonucleotide probe (FP) is s
standard of efficiency of sodiumarsenite treatment;β-actinwas u
on NF-κB-dependent luciferase reporter activity and FAS- and Fa
2xNF-κB-Luc, −460 FASpr-Luc, −453 FasLpr-Luc and tk-Luc (vector
was normalized based on βGal activity; βGal expression constru
mean ± SD from three independent experiments. (C) Immunopre
anti-FasL mAb (NOK-1) was followed by Western blot analysis w
used as a negative control. WM794 cells were treated with sodiu
levels 16 h after treatment of indicated melanoma cells with arse
staining with mAb (NOK-1), PE-conjugated goat anti-mouse seco
of surface FasL in melanomas were equal to nonspecific staininginhibition of NF-κB p65–p50 DNA-binding activity and NF-
κB reporter activity (Figs. 2A and B). It has been reported that
sodium arsenite treatment strongly induced the MAPK
pathways and activated ERK, p38 and JNK [58], this was
followed by induction of heme-oxygenase-1 (HO-1) tran-
scription and translation, a hallmark of oxidative stress.
Consequently, we used Western blot analysis of HO-1
protein levels to confirm of the effectiveness of sodium
arsenite treatment (Fig. 2A).Ligand gene expression in human melanoma cells.
B activity. EMSA was performed for determination of NF-κB
hown. Western blot analysis of HO-1 levels was used as a
sed as a protein loading control. (B) Effects of sodium arsenite
sL promoter activities. The reporter constructs used are:
with thymidine kinase promoter). Luciferase reporter activity
ct was cotransfected at the ratio 1/4. Error bars represent
cipitation of total FasL protein fromWM793 cell extracts with
ith anti-FasL mAb (clone G247-4). Nonspecific mouse IgG was
m arsenite (5 μM) for 16 h. (D) Determination of surface FasL
nite (5 μM) or with GM1489 (10 μM), an MMP inhibitor, using
ndary Ab and the flow cytometry. Control (non-treated) levels
(ns). MFI is indicated in brackets.
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sodium arsenite treatment might also have regulatory
effects on the endogenous Fas and FasL gene expression
in melanomas via modulation of AP-1 (c-Jun/ATF2) and NF-
κB-dependent transcription. Since AP-1 transcription factor
plays a negative role in the regulation of the Fas gene
transcription [38] while NF-κB is the positive regulator of
this gene [28], we indeed observed a strong negative
response of the Fas gene promoter activity following
sodium arsenite treatment (Fig. 2B). On the other hand,
consequences of arsenite treatment in the regulation of the
FasL transcription are quite difficult to predict because both
AP-1 and NF-κB play positive role in this regulation among
several other transcription factors, such as c-Myc, SP-1, NF-
AT and EGR [46,59–62]. Basal FasL promoter activity was
easily detectable in WM793 cells. Furthermore, sodium
arsenite, even at low doses (1–2 μM), had notable negative
effects on the human FasL gene promoter activity in this
cell line and strongly suppressed both the basal FasL
promoter and Fas promoter activities at higher concentra-
tions (Fig. 2B).
Due to suppression of the Fas promoter activity and
transcription by arsenite and continuous internalization
and degradation of the surface receptor, the levels of Fas
protein on the cell surface started to decrease 16–24 h after
arsenite treatment (data not shown). Total levels of the
membrane form of the FasL protein (p45) were determined
by immunoprecipitation of WM793 cell extracts with
subsequent Western blot analysis. Sodium arsenite treat-
ment (after 16 h) caused notable downregulation of total
FasL protein level, probably, as a result of protein degra-
dation (Fig. 2C). However, the membrane form of FasL could
not be practically detected on the cell surface of WM793
and LU1205 melanoma cells before and after sodium
arsenite treatment using immunostaining with anti-FasL
mAb (NOK-1) and the FACS analysis (Fig. 2D). Negative
effects of arsenite on the FasL transcription and total FasL
protein levels have been previously observed in some cell
lines [63,64].
Intracellular expression of FasL in WM793 and LU1205
melanoma cells and the absence of surface expression of this
protein appear to indicate the existence of additionalmechan-
isms, which prevent FasL translocation or cause rapid
destabilization of FasL on the cell surface. Surprisingly,
pretreatment of WM793 and LU1205 cells with several
different matrix metalloproteinase inhibitors, such as 100 μM
phenanthroline and 10 μM GM1489 (which had been previ-
ously implicated in suppression of FasL processing [65–67]),
had only modest effects on the upregulation of surface FasL
expression (Fig. 3D and data not shown). It indicated a
relatively minor role of FasL cleavage in these lines of
melanomas. Our next aim was to identify conditions for
increasing the efficiency of translocation and stabilization of
FasL protein on the surface of melanoma cells.
COX-2 inhibition upregulates arsenite-induced apoptosis in
Fas-positive melanomas
We and others have previously demonstrated that simulta-
neous treatment of cancer cells with sodium arsenite inaddition to specific inhibitors of cell survival pathways may
dramatically increase apoptosis [34,35,68]. It has been estab-
lished that many types of cancer cells, including melanomas
[69], containhigh levels of COX-2 activity. These levels canonly
be achieved in normal cells by stimulationwith growth factors
and cytokines [29,70,71]. Active anti-apoptotic functions of
COX-2 in cancer cells have been widely reported [72–74].
Furthermore, COX-2 is one of the several important genes,
which mediate breast cancer metastasis to the lung [75]. In
present study, we wanted to determine whether pharmaco-
logical inhibition of COX-2 activity might increase levels of
arsenite-induced apoptosis in melanoma cells.
Western blot analysis demonstrated high basal levels of
COX-2 protein in several melanoma lines (Fig. 3A). Normal
human lung fibroblasts, which were treated with IL-1β and
TNFα, served as a positive control of COX-2 induction at the
protein levels in the normal, non-cancerous, cells (Fig. 3A).
Furthermore, determination of the total COX-2 levels (after
cell permeabilization) by FACS analysis in several melanoma
cell lines confirmed presence of high levels of COX-2 in WM9
and LOX cells and average levels in LU1205 and WM793 cells
(Fig. 3B). Specific inhibition of COX-2 activity by NS398 (50 μM)
alone had no considerable effects on induction of apoptosis in
melanoma cells. However, combined treatment with sodium
arsenite (5 μM) and NS398 (50 μM) synergistically increased
apoptosis in Fas-positive melanomas WM793, LU1205, WM9
and LOX 16 h and 30 h after treatment (Figs. 3C, D). Total levels
of cell death of melanomas induced by combined treatment of
sodium arsenite and NS398 were somewhat higher than
apoptotic levels due to the secondary necrosis (Fig. 3C and
data not shown).
To evaluate a probable role of the FasL–Fas-mediated
death in arsenite and NS398-treated melanomas, we first
determined levels of surface expression of Fas and FasL
following such treatment. We observed a marginal effect on
the surface Fas receptor levels after treatment of melano-
mas with arsenite and NS398. TNFα stimulation was used as
a positive control for upregulation of Fas levels (Fig. 4A). In
contrast, the surface levels of FasL were notably increased
16 h after combined treatment with sodium arsenite and
NS398 in WM9, LU1205 (Fig. 4B), WM793 and LOX melanoma
cells (data not shown). Arsenite or NS398 alone did not
induce a notable expression of FasL on the cell surface (Fig.
4B). Anti-FasL inhibitory mAb (NOK-1) partially suppressed
apoptosis induced with arsenite and NS398 in all melanoma
lines tested, while effect of anti-TNFα mAb was pronounced
only in WM793 cells (Fig. 4C). This effect of anti-TNF mAb on
WM793 cells was likely due to inhibition of arsenite-induced
TNFα-mediated apoptosis in these cells [34]. To demonstrate
a dependence of apoptosis induced by arsenite and NS398
on caspase activities, we used specific inhibitors of cas-
pases. Both Ac-IETD-CHO (an inhibitor of caspase-8 and
caspase-6) and Ac-LEHD-CHO (an inhibitor of caspase-9)
partially suppressed arsenite and NS398-induced apoptosis,
although Ac-IETD-CHO was more effective (Fig. 4D), indicat-
ing that death-receptor/caspase-8-mediated cascade operat-
ed during apoptosis. A general caspase inhibitor, zVAD-fmk
(5 μM), was quite efficient for suppression of apoptosis,
although this suppression was not complete, likely due to
secondary necrosis (Fig. 4D).
Fig. 3 – COX-2 expression in human melanomas. (A) Western blot analysis of COX-2 levels in the indicated cell lines. β-actin
was used as a loading control. Normal human lung fibroblastswere untreated or treatedwith IL-1 (2 ng/ml) and TNFα (10 ng/ml)
for 4 h. (B) Total COX-2 levels in human melanomas have been determined by FACS analysis after cell permeabilization and
staining using mAb against COX-2, PE-conjugated goat anti-mouse secondary Ab and the flow cytometry. Nonspecific (ns)
staining; medium fluorescence intensity (MFI) is indicated in brackets. (C, D) Inhibition of COX-2 activity by NS398 (50 μM) had
synergistic effects on arsenite-induced apoptosis in COX-2-positive human melanomas. Levels of apoptosis have been
determined by FACS analysis of PI-stained melanoma cells 16 h (C) and 30 h (D) after treatment with sodium arsenite (5 μM),
NS398 (50 μM) or their combination; levels of total cell death have been determined by Trypan blue staining. Error bars
represent mean ± SD from three independent experiments.
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lation of the surface FasL expression in several melanoma
lines following the combined treatment with arsenite and
COX-2 inhibitor could potentially explain an increase in the
apoptotic response. Hence, in addition to basal apoptosis
driven by sodium arsenite (which was TNFα-mediated in
WM793 cells), combined treatment with sodium arsenite and
NS398 induced FasL–Fas-mediated apoptosis in melanoma
cells.
Regulation of the FasL expression by combined treatment with
sodium arsenite and NS398
There are several possible targets for modulation of FasL
expression on the cell surface: (i) the FasL promoter activity
and subsequent transcription and translation; (ii) posttrans-
lational modifications of FasL; (iii) FasL protein translocation
from the cytoplasmic pool through secretory lysosomes
[47,48] to the cell surface; (iv) membrane FasL internalization
and degradation; (v) membrane FasL cleavage on the cell
surface by matrix metalloproteinases (that resulted insecretion of the soluble FasL). In addition, tumor cell
secretion of FasL-bearing microvesicles has been described
[7]. Interestingly, FasL promoter activity and transcription
were partially suppressed by sodium arsenite treatment (Fig.
2B). Furthermore, the COX-2 inhibitor NS398 alone, or in the
combination with sodium arsenite, was also an effective
suppressor of the NF-κB transactivation and the FasL
promoter activity and transcription in melanomas (Fig. 5A).
Negative regulation of NF-κB activity by COX-2 inhibitors has
been well documented [72]. Experimental results obtained
indicate that posttranslational regulation of the FasL, rather
than regulation of the FasL gene transcription, might be
responsible for increased surface expression of FasL 10–16
h after treatment with sodium arsenite and NS398 (Figs. 4B,
5B). This FasL translocation from the cytoplasm to cell
surface is an active process that is generally dependent on
new protein synthesis including synthesis of some helper
proteins. The presence of cycloheximide (CHX) (1–5 μg/ml),
an inhibitor of translation, indeed suppressed positive effects
of combined treatment of arsenite and NS398 on the surface
FasL levels (Fig. 5B), thereby linking regulation of the surface
Fig. 4 – Upregulation of the surface FasL levels after treatment of melanoma cells with a combination of NS398 and sodium
arsenite. (A) Surface Fas levels after treatment of indicatedmelanomaswith sodiumarsenite (5μM)andNS398 (50μM). TNFα (10
ng/ml) was used as a positive regulator of Fas expression. Control non-treated cells (Control) and nonspecific (ns) staining cells
with IgG-PE are indicated. (B) Surface FasL levels were determined using anti-FasL mAb (NOK-1) and PE-conjugated goat
anti-mouse secondaryAb in flowcytometry. Control (non-treated) levels of FasLwere the sameasnonspecific (ns) staining. Only
combined treatment with As (5 μM) and NS398 (50 μM) induced specific and pronounced changes in the surface FasL levels of
melanoma cells. (C) Pretreatment of the cell cultures with anti-FasL inhibitory mAb (NOK-1) (2 μg/ml) or with anti-TNFαmAb
partially suppressed apoptosis in the indicated melanoma cell lines, which was induced by dual treatment of sodium arsenite
and NS398. (D) Effects of caspase inhibitors (10 μM) on apoptosis in melanoma cells, induced by sodium arsenite and NS398.
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Fig. 5 – Expression of endogenous and transfected FasL on the cell surface ofmelanomas. (A) Effects of combined treatmentwith
sodium arsenite and NS398 on the FasL promoter activity; −1.3 kb FasLpr-Luc and 2xNF-κB-Luc constructs were used for
luciferase assay. (B) Effects of cycloheximide (CHX) (2 μg/ml) on surface FasL levels induced by arsenite and NS398 in WM793
and WM9 melanoma cells. (C) Protein levels of FasL in WM9 cells after indicated treatment were determined using
immunoprecipitation with mAb against human FasL (NOK-1) and Western blot analysis with anti-FasL mAb (clone 247-4).
Position of membrane FasL (p45) is indicated. H is heavy chains of mouse IgG. (D) WM9 cells were transfected with GFP-FasL
expression construct. Sixteen hours after transfection, cells were treated with arsenite (As), NS398 or combination of As and
NS398. Confocal analysis of FasL-GFP translocation to the cell surface ofWM9melanomawas performed 30min after treatment
with arsenite (5μM) andNS398 (50μM). Surface expression of FasLwas detected usingmAb (NOK-1) against the surface epitope
of FasL and the secondary anti-mouse Ab labeled with Texas Red.
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trafficking.
As it was previously mentioned (Fig. 2D), inhibition of
matrix metalloproteinase (MMP) activities, which were
involved in cleavage of the membrane form of FasL
[65,67,76], had only modest positive effects on the surface
levels of FasL in human melanoma lines indicating that themembrane FasL cleavage was not well pronounced in these
cancer cells. Immunoprecipitation of total cell extracts by
anti-FasL mAb and Western blot analysis demonstrated an
upregulation of the total FasL protein level 12 h after
combined treatment of WM9 cells with arsenite and NS398
likely due to an increased stability of FasL protein on cell
surface (Fig. 5C).
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pool to the cell surface by combined treatment of melanoma
cells with sodium arsenite and COX-2 inhibitor
To evaluate the effects of NS398 and sodium arsenite on the
translocation of FasL to the cell surface, we transfected WM9
cells with GFP-tagged FasL (GFP-FasL) expression construct
(Fig. 5D). Sixteen hours after transfection, 23% ± 7% of GFP-
FasL-transfected (green) cells expressed FasL on their surface
(determined by staining with NOK-1 mAb and FACS analy-
sis). According to results described previously [47,48], an
induced GFP-FasL translocation from the cytoplasm to the
cell surface was a relatively rapid process. Indeed, 30 min
after treatment of GFP-FasL-transfected cells with sodium
arsenite or especially after combined treatment with arse-
nite and NS398, the surface expression of FasL (determined
with NOK-1 mAb and FACS analysis) substantially increased:
from 29% to 57% positive cells. NS398 alone was not reallyFig. 6 – GFP-FasL translocation to the cell surface. WM9 melano
hours after transfection, cells were not treated or treated with ar
cells were stained with anti-FasL mAb (NOK-1), which recognize
PE-conjugated goat anti-mouse Ab and analyzed by flow cytomet
total number of GFP-positive transfected cells is indicated in braeffective. This initial increase in FasL surface expression was
followed by a significant decline of this level 2–6 h after
treatment (Fig. 6 and data not shown). Confocal microscopy
with anti-FasL mAb (NOK-1, against the extracellular domain
of human FasL) also demonstrated surface expression of
GFP-FasL in some treated cells (Fig. 5D). These observations
provide a direct proof of the role of arsenite and NS398 in
the upregulation of the FasL translocation to the cell surface.
Thus, combined treatment of melanoma cells with NS398
and arsenite increased and stabilized protein levels of FasL
in the cells and synergistically increased FasL translocation
from the cytoplasmic pools to cell surface.
COX-2 downregulation by specific RNAi
As an alternative approach for suppression of COX-2,
silencing COX-2 expression with COX-2 RNAi has been
used. We designed and created COX-2 RNAi expressionma cells were transfected with FasL-GFP construct. Sixteen
senite (5 μM) and NS398 (50 μM) for the next 0.5–2 h. Then,
s the surface epitope of FasL, and with the secondary
ry. A normalized ratio of the surface FasL-positive cells to the
ckets.
1412 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 2 ( 2 0 0 6 ) 1 4 0 1 – 1 4 1 7construct based on pSR-GFP/Neo vector from Oligoengine
(Seattle, WA). Following transfection by COX-2 RNAi or the
empty vector and subsequent selection in the presence of
G418, two mass cultures of WM793 melanoma enriched with
COX-2 RNAi/GFP or vector/GFP were established. In both
types of transfected cells, GFP was localized in the cytoplasm
and in the nucleus (Fig. 7A). Determination of COX-2 protein
levels by Western or FACS analysis demonstrated a down-
regulation of basal COX-2 protein levels by COX-2 RNAi
expression in WM793 cells (Figs. 7B and C). Interestingly, thisFig. 7 – Downregulation of COX-2 protein levels by targeting of
upregulation of FasL expression and acceleration of arsenite-ind
designed to target human COX-2 mRNA within nucleotides 354–
which also produced a marker GFP protein. Human melanomaW
been used for COX-2 silencing. Two mass cultures of WM793 cel
with the COX-2 RNAi expression construct and subsequently sel
localized in the cytoplasm and in the nucleus of transfected cells
cultures were detected by Western analysis. (C) FACS analysis o
antibody and the secondary anti-mouse Ab labeledwith PE confir
cells from 8 MFI to 2 MFI. (D) Sodium arsenite (As, 5 μM) treatmen
increased surface expression of FasL. FACS analysis was perform
Annexin-V-PE-positive (red) apoptotic cells among transfected G
Treatment of WM793 cells with arsenite, NS398 or their combinawas accompanied by upregulation of the surface FasL levels
in transfected cells after arsenite treatment (Fig. 7D). The
percentage of Annexin-V-PE positive (red) apoptotic cells
substantially increased after treatment of WM793/COX-2-
RNAi (green) cells by sodium arsenite (Fig. 7E). A combination
of arsenite and NS398 increased levels of apoptosis in control
cells, which were transfected with the empty pSR-GFP/Neo
vector. Taken together, these data demonstrated relatively
similar effects on the FasL surface expression and arsenite-
induced apoptosis either after pharmacological inhibition ofCOX-2 mRNA with specific RNAi of 19 nucleotides leads to
uced apoptosis in human melanoma WM793. (A) RNAi,
372, was expressed using pSR-GFP/Neo (Cox-2-RNAi) vector,
M793 cell line with moderate basal expression of COX-2 has
ls were obtained after transfection with the empty vector or
ected in the presence of G-418 (400 μg/ml). GFP expression is
. (B) Total protein levels of COX-2 expression in selected
f transfected and selected cells using monoclonal anti-COX-2
med a downregulation of COX-2 levels inWM793/COX-2 RNAi
t of control (Vector) and COX-2 knockdown cells dramatically
ed as indicated in the legend to Fig. 4. (E) Percentage of
FP-positive cells was determined using FACS analysis.
tion was performed for 12 h.
Fig. 8 – Regulation of surface expression of FasL in human melanomas and prostate adenocarcinomas. (A) Effects of MG132, a
proteasome inhibitor, on upregulation of surface FasL levels in melanoma cells. WM9 cells were treated with 20 μM MG132.
Surface FasL levels were determined using anti-FasL mAb (NOK-1) and PE-conjugated goat anti-mouse secondary Ab in flow
cytometry. Control (non-treated) levels of FasL were the same as nonspecific staining. (B) Protein levels of FasL in WM9 cells
after treatment with MG132 were determined using immunoprecipitation withmAb against human FasL (NOK-1) andWestern
blot analysis with anti-FasLmAb (clone 247-4). Position ofmembrane FasL (p45) is indicated. (C) Cell cycle–apoptosis analysis of
WM9 cells after treatmentwithMG132with nonspecific IgG or withMG132 in the presence of anti-FasLmAb (NOK-1; 5μg/ml in
the medium). (D) Effects of phenylarsine oxide (PAO; 1 μM), an inhibitor of endocytosis and protein-tyrosine phosphatases, on
surface levels of FasL (FACS analysis). (E) Induction of surface FasL expression in prostate cancer cell lines by arsenite and
NS398 treatment (FACS analysis).
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by RNAi.
Effects of inhibition of the proteasome on FasL surface
expression
There was a close similarity between combined treatment of
melanoma cells with arsenite and NS398 and treatment with
MG132, a proteasome inhibitor. Inhibition of the proteasome
activity increased both FasL total protein level and FasL surface
expression (Figs. 8A and B). As a result of this treatment, FasL-
mediated apoptosis was induced, which could be partially
blocked by pretreatment of cell cultures with the inhibitory
anti-FasL mAb (Fig. 8C). The ubiquitin–proteasome-mediated
pathway plays a universal role in the regulation of protein
stability, including stability of ligands, their internalizationand
degradation by the 26S proteasome complexes or by lysosomes
[77–79]. A possible role for sodium arsenite in the regulation of
the proteasome activity has been described previously [80].
Furthermore, arsenite treatment suppressed transcription of
some proteasome components, as was observed using cDNA
microarray analysis [81]. In contrast, COX-2 inhibitors have
been shown to suppress transcription of several matrix
metalloproteinases and to upregulate Dynamin-2 gene expres-
sion, which controls protein export and endocytosis in the cell
[72,82,83]. General inhibition of endocytosis in melanomas by
phenylarsine oxide (PAO; 1 μM) [84], which appears to suppress
recyclingmembrane FasL, also substantially increased surface
expression of FasL (Fig. 8D). Taken together, these data
demonstrated that a combination of sodium arsenite and
NS398 induced upregulation of the surface FasL levels thatwas
based on an increase in the efficiency of translocation to the
cell surface, as well as stabilization of FasL protein at the cell
surface, rather than on acceleration of the FasL gene transcrip-
tion. This phenomenon was not restricted to melanomas;
combined treatment with NS398 and arsenite also induced
FasL surface expression in two lines of prostate adenocarcino-
mas, LnCAP and Du145 (Fig. 8E).Discussion
Numerous studies suggest that cyclooxygenase-2 (COX-2)may
be auseful target for anticancer therapy. The twomain reasons
for this suggestionare: (i) COX-2 is overexpressed in a variety of
tumors, which have profoundly increased synthesis of pros-
taglandins; (ii) COX-2 exhibits a strong anti-apoptotic activity
via prostaglandin synthesis [29,71,85]. There are certain
limitations for the direct application of this approach to the
treatment of melanomas; COX-2 is present in most melano-
mas at a moderate level, and COX-2 inhibitors alone do not
induce apoptosis in this type of tumors. There are significant
advantages in using combined therapy for cancer treatment.
Since FasL expression and activity could be “naturally”
restored in highly metastatic tumors through epigenetic
and genetic changes [1,4,5], we have attempted to evoke
FasL-mediated apoptotic death in Fas-positive melanomas.
Our first attempt was to modulate the FasL transcription
[45,46,59,61,86–88]. A combination of COX-2 inhibitor (for
suppression of PGE2 production and PGE2-induced signalingcascades) and sodium arsenite as a powerful inducer of the
MAPK pathways was very effective in upregulating apoptosis
in COX-2-positive melanomas. Unexpectedly, this dual treat-
ment actually downregulated the FasL promoter activity
shifting regulation of the FasL expression in melanomas to
mechanisms controlling FasL protein translocation and
stability. The presence of intracellular pools of FasL protein
was previously observed in different cell systems, which
included cancer cell lines [7,47,48,89,90]. This pool of protein
could allow for a temporary increase in the surface FasL
expression even though activity of the FasL promoter and
FasL transcription is decreased.
Sensitization of cancer cells to FasL–Fas mediated apopto-
sis has been widely studied, including INF-γ-dependent FasL
induction in prostate cancer cells [91] and the similar
induction after suppression of AKT signaling [92]. As a rule, a
transcriptional activation of the FasL gene is themain target of
such investigations [62,93]. We have now demonstrated that
translocation of FasL protein from the cytoplasm to the cell
surface and stability of this protein may be an important
mechanism for regulating FasL surface expression, at least in
melanomas and prostate cancer cells. Interestingly, over-
expression of Par-4 protein has been reported to drive
trafficking of both Fas and FasL in some prostate cancer cells
[90]. Although we have not been able to detect significant
effects of Par-4 overexpression on the FasL translocation, we
have observed changes in Fas surface expression in melano-
ma cells (data not published). Effects of Par-4 on cell signaling
and FasL translocation appear to be quite different from the
effects of the combined treatment of sodium arsenite and
NS398. Re-evaluation of the role of the surface expression of
membrane FasL as a critical target for combined therapy of
cancer cells, which was demonstrated in present study, may
open new possibilities in anticancer treatment.Acknowledgments
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